Standalone figures · ₹ crore · years without a filed annual are summed from quarters
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 580 | 711 | 1,001 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | |
| COGS | -414 | -479 | -276 | 1,047 | 1,065 | 1,103 | 1,571 | 1,547 | 1,397 | 1,392 | 1,487 |
| Gross profit | — | — | — | 638 | 829 | 864 | 614 | 670 | 736 | 687 | 832 |
| 943 | 1,088 | 1,153 | 228 | 256 | 272 | 357 | 444 | 504 | 485 | 563 | |
| 51 | 102 | 124 | 410 | 574 | 592 | 256 | 227 | 232 | 202 | 269 | |
| OPM % | 8.9% | 14.4% | 12.4% | 24.3% | 30.3% | 30.1% | 11.7% | 10.2% | 10.9% | 9.7% | 11.6% |
| Depreciation | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 |
| Interest | 61 | 67 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 |
| 0 | — | 2 | 10 | 16 | 24 | 18 | 26 | 30 | 22 | 10 | |
| Profit before tax | -39 | 5 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 184 |
| Tax | -3 | 1 | 4 | 99 | 172 | 127 | 57 | 50 | 47 | 37 | 47 |
| Tax % | -6.7% | 22.8% | 11.5% | 29.6% | 32.3% | 22.2% | 25.7% | 26.1% | 25.9% | 26.8% | 25.3% |
| -36 | 4 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 138 | |
| PAT margin % | -6.2% | 0.6% | 2.8% | 14% | 19.1% | 22.6% | 7.6% | 6.3% | 6.4% | 4.9% | 5.9% |
| EPS (₹) | -7.2 | — | 4.9 | 42.1 | 127 | 76.2 | 28.2 | 23.8 | 23.1 | 3.4 | 4.7 |
| EPS adjusted (₹) | — | 0.2 | 1 | 8.3 | 12.7 | 15.1 | 5.6 | 4.8 | 4.6 | 3.4 | 4.7 |
| — | — | 0% | 0% | 2.4% | 7.9% | 14.2% | 16.8% | 21.7% | 116.3% | — | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 128 | 160 | 417 | — | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 | 1,740 |
| 438 | 393 | 258 | — | 0 | 43 | 80 | 33 | 117 | 132 | |
| 150 | 243 | 210 | — | 350 | 527 | 434 | 600 | 577 | 656 | |
| Total equity & liabilities | 772 | 852 | 942 | — | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 |
| 399 | 406 | 27 | 469 | 512 | 561 | 751 | 933 | 1,170 | 1,178 | |
| CWIP | 4 | 7 | 1 | — | 48 | 102 | 81 | 100 | 21 | 94 |
| Investments | 0 | 0 | 0 | — | 1 | 2 | 20 | 21 | 21 | 21 |
| 369 | 439 | 914 | — | 1,048 | 1,295 | 1,168 | 1,191 | 1,170 | 1,294 | |
| Total assets | 772 | 852 | 942 | — | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharmaceutical | 1,396.25 | 172.27 | 1,512.64 | 196.6 | 1,316.04 | 13.09 |
| Chemical | 1,160.53 | 30.24 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 83 | 120 | 273 | 471 | 380 | 91 | 123 | 291 | 179 | 214 | |
| -23 | -50 | -63 | -184 | -317 | -120 | -119 | -192 | -154 | -198 | |
| -60 | -70 | -197 | -272 | -58 | -2 | -4 | -93 | 46 | -29 | |
| Net cash flow | 1 | -1 | 13 | 15 | 4 | -31 | -0 | 7 | 70 | -13 |
| Free cash flow | 61 | — | 213 | — | 272 | -62 | -88 | 17 | -35 | 41 |
| CFO / Operating profit % | 81.5% | 96.6% | 66.7% | 82% | 64.2% | 35.5% | 54.4% | 125.6% | 88.4% | 79.7% |
| 578.66 |
| 297.72 |
| 280.94 |
| 10.76 |
| Unallocated | 21.28 | 0 | 495.42 | 294.02 | 201.4 | 0 |
₹ crore by fiscal year